Refeyn

Refeyn is a private, revenue-generating company commercializing a novel analytical platform based on mass photometry. This technology allows for the rapid characterization of biomolecules—such as proteins, antibodies, and gene therapy vectors—by measuring their mass at the single-particle level without labels. The company targets the growing markets in biopharmaceutical development, particularly for cell and gene therapy analytics and structural biology. Its business model is primarily platform-based, selling instruments (TwoMP, MyMassMP, SamuxMP, KaritroMP) and consumables to research and industrial labs.

Mass photometry: a label-free, single-particle analysis technology that measures molecular mass in solution by detecting light scattering changes, enabling rapid characterization of proteins, antibodies, and viral vectors.

Refeyn competes with established analytical techniques like Size-Exclusion Chromatography (SEC), Analytical Ultracentrifugation (AUC), and Dynamic Light Scattering (DLS), often offered by large players like Agilent, Malvern Panalytical, and Wyatt Technology. Its unique value proposition is single-particle, label-free mass measurement in solution. It may also face competition from other emerging label-free detection methods and specialized microscopy techniques, but currently holds a pioneering position in commercializing mass photometry.